BB13803-NCT07152379

Study Title
An Open-label, Controlled Phase 2 Study Assessing a Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
Sponsor Name
Cerus Corporation
NCT Number
NCT07152379
IDE Number
BB13803
CMS Approval Date
2026-07-17
Clinical Trial Link
https://www.clinicaltrials.gov/study/NCT07152379
Category
A